Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

Makoto Ueno, Junji Furuse, Satoshi Kobayashi et al.|˜The œLancet. Gastroenterology & hepatology|2019

Cited by 331